Please login to the form below

Not currently logged in
Email:
Password:

PCSK9 inhibitors

This page shows the latest PCSK9 inhibitors news and features for those working in and with pharma, biotech and healthcare.

MS and cholesterol drugs picked for new UK rapid uptake push

MS and cholesterol drugs picked for new UK rapid uptake push

baby. PCSK9 inhibitors for treatment of primary hypercholesterolaemia and mixed dyslipidaemia  - Cost-effective drugs that significantly lower cholesterol.

Latest news

  • CETP inhibitor class finally dies as Merck abandons anacetrapib CETP inhibitor class finally dies as Merck abandons anacetrapib

    The drug follows in the footsteps of other CETP inhibitors - including Pfizer's torcetrapib, Roche's dalcetrapib and Eli Lilly's evacetrapib - although those candidates all failed to show a benefit ... In the interim almost all of those brands have

  • Merck & Co's anacetrapib data fails to generate much excitement Merck & Co's anacetrapib data fails to generate much excitement

    contend in the statin add-on market with PCSK9 inhibitors such as Amgen's Repatha, which showed a larger (15%) risk reduction in the FOURIER trial but are still struggling to ... If Merck does choose to abandon anacetrapib the drug will follow several

  • Merck & Co's anacetrapib rescued by positive phase III trial Merck & Co's anacetrapib rescued by positive phase III trial

    cholesterol-lowering drugs now that the PCSK9 inhibitors - Amgen's Repatha (evolocumab) and Sanofi/Regeneron's Praluent (alirocumab) - are being used alongside statin therapy. ... CETP inhibitors are designed to increase levels of high-density

  • Repatha outcomes data Repatha outcomes data "less than stellar"

    than stellar." Investors are now more cautious on prospects for PCSK9 inhibitors as a result, he suggested in a research note. ... It is one of only two PCSK9 inhibitors on the market, along with Sanofi and Regeneron's Praluent (alirocumab) which is also

  • Praluent can stay on market for now, says US court Praluent can stay on market for now, says US court

    Both drugs are PCSK9 inhibitors that have been approved in the US to help patients who cannot meet their cholesterol targets with existing therapy, such as statin drugs, or who have ... Praluent was approved in the US first, but Amgen has so far won the

More from news
Approximately 1 fully matching, plus 32 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics